Clinical Trial Update: Study of Pembrolizumab (MK-3475) Monotherapy in Locally Advanced/Metastatic Renal Cell Carcinoma (MK-3475-427/KEYNOTE-427) [Phase 2]

View source ↗

Summary

Phase 2 study of pembrolizumab monotherapy in locally advanced or metastatic renal cell carcinoma has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Renal Cell Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2022-05-11